ArticleBMC immunology2025
The relationship between the biological biomarker lnc-DC and female patients with Sjögren's disease.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveLaboratory diagnostic markers and clinical presentations of Sjögren’s disease (SjD) may vary by sex. This study aimed to investigate the association between lnc-DC expression and female SjD and to evaluate its potential as a diagnostic biomarker in female SjD patients.
methods599 SjD patients were retrospectively analyzed in this cohort, additionally 337 healthy adults without autoimmune diseases served as the healthy control group (HC). Adjusted p - values are reported for all exploratory analyses. Associations between diverse clinical parameters and SjD occurrence among female SjD patients were assessed using Cox proportional hazards models. To account for multiple hypothesis testing across 40 comparisons, we applied the Benjamini-Hochberg false discovery rate (FDR) correction with q = 0.05. Subsequently, receiver operating characteristic (ROC) curves were constructed to evaluate the diagnostic performance of lnc-DC expression levels in distinguishing female SjD patients.
resultsAfter a retrospective observation for median 44 months (Interquartile Range (IQR): 35–55 months), symptoms such as dry mouth, joint pain, reduced tear flow, elevated IgM concentrations, increased ESSDAI scores, and higher detection rates of rheumatoid factor (RF), anti-Ro52 antibody, and anti-SSA antibody were significantly more prevalent among female patients (all p < 0.05). Moreover, female participants exhibited substantially increased levels of lnc-DC expression (p < 0.001). In contrast, males displayed a higher prevalence of parotid gland enlargement and interstitial lung disease (ILD) (both p < 0.001). Cox proportional hazards models identified elevated lnc-DC expression as an independent predictor for SjD development in females (p < 0.001). After FDR correction, elevated lnc-DC remained significantly associated with SjD status (adjusted p < 0.001). Other biomarkers did not survive correction (adjusted p > 0.05). Additionally, ROC curve analysis demonstrated that elevated lnc-DC levels effectively distinguished female SjD patients, with an area under the curve (AUC) of 0.83, sensitivity of 78.64%, and specificity of 73.61%, p < 0.001.
conclusionsFemale SjD patients exhibited significantly elevated lnc-DC expression. When integrated with conventional serological markers, lnc-DC enhanced SjD diagnostic accuracy. These findings suggest lnc-DC as a sex-specific adjunct biomarker for SjD clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.